News
In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...
GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...
British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...
GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...
CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...
GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.01% to 9,136.94. GSK PLC ...
SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...
Second-quarter sales rose to £7.99 billion from £7.88 billion in the same period the year prior.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results